

## BMJ Open Respiratory Research

### Sudden death in patients with sleep apnea: a systematic review and meta-analysis

Journal:	<i>BMJ Open Respiratory Research</i>
Manuscript ID	bmjresp-2020-000656
Article Type:	Original research
Date Submitted by the Author:	02-Jun-2020
Complete List of Authors:	Heilbrunn, Emily; Penn State University Park Ssentongo, Paddy; Penn State University Park Chinchilli, Vernon; Penn State Health Milton S Hershey Medical Center, Public Health Sciences Ssentongo, Anna; Penn State University Park,
Twitter User Name:	annassentongo
Keywords:	Sleep apnoea, Clinical Epidemiology

SCHOLARONE™  
Manuscripts

medRxiv preprint doi: <https://doi.org/10.1101/2020.05.06.20093641>; this version posted June 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Sudden death in patients with sleep apnea: a systematic review and meta-analysis**  
4  
5  
6  
7

8  
9 **Emily S. Heilbrunn, BS<sup>1</sup>, Paddy Ssentongo, MD, MPH<sup>1,3</sup>, Vernon M. Chinchilli, PHD<sup>1</sup>,**  
10  
11 **Anna E. Ssentongo, MPH<sup>1,2</sup>§,**  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

30 Word count: 1951  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 Corresponding author

42 Anna Ssentongo

43 500 University Drive

44 Hershey, PA 17033

45 Pennsylvania State University

46 USA, Tel: 814-404-5208

47 Email: [assentongo@pennstatehealth.psu.edu](mailto:assentongo@pennstatehealth.psu.edu)  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Abstract:

Background: Over 1 billion individuals across the globe experience some form of sleep apnea, and this number is steadily rising. Obstructive sleep apnea (OSA) can negatively influence one's quality of life and potentially increase the risk of mortality. However, this association between OSA and mortality has not been comprehensively and thoroughly explored. This meta-analysis was conducted to conclusively estimate the risk of death for all-cause mortality and cardiovascular mortality in OSA patients.

Study Design: 4,613 articles from databases including PUBMED, OVID & Joana Briggs, and SCOPUS were comprehensively assessed by two reviewers (AES & ESH) for inclusion criteria. 28 total articles were included, with 22 of them being used for quantitative analysis. Pooled effects of all-cause mortality, cardiac mortality, and sudden death were calculated by utilizing the metaprop function in R Statistical Software and the random-effects model with appropriate 95% confidence intervals.

Results: Analysis on 42,032 individuals revealed that those with OSA were twice as likely to die from cardiac mortality compared to those without sleep apnea (HR= 1.94, 95%CI 1.39-2.70). Likewise, individuals with OSA were 1.7 times as likely to die from all-cause sudden death compared to individuals without sleep apnea (HR= 1.74, 95%CI 1.40-2.10). There was a significant dose response relationship between severity of sleep apnea and incidence risk of death, where those with severe sleep apnea were

Conclusions: Individuals with obstructive sleep apnea are at an increased risk for all-cause mortality and cardiac mortality. Further research related to appropriate interventions and treatments are necessary in order to reduce this risk and optimize survival in this population.

1  
2  
3 **Key Messages:**

4  
5 **What is the key question?**

6  
7  
8 Are individuals with sleep apnea at an increased risk for cardiovascular mortality and  
9  
10 sudden death?

11  
12 **What is the bottom Line?**

13  
14  
15 Sleep apnea is associated with an increased risk of cardiovascular mortality and sudden  
16  
17 death, with a dose response relationship, where those with severe sleep apnea are at the highest  
18  
19 risk of mortality.  
20

21  
22 **Why read on?**

23  
24 This is the first systematic review and meta-analyses to synthesize and quantify the risk of  
25  
26 mortality in those with sleep apnea, highlighting important directions for future research.  
27  
28  
29  
30  
31  
32

33 **Prospero Registration ID: CRD42020164941**  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Introduction:

Obstructive sleep apnea (OSA) is a chronic sleep disorder, in which the patient experiences complete or partial obstruction of the upper airway structures [1-2]. This then results in a reduction or complete blockage of airflow during sleep, intermittent hypoxia, and sleep disturbances [3]. Common symptoms of OSA, such as excessive daytime sleepiness, fatigue, heavy snoring, and non-refreshing sleep have the potential to play an influential role in one's quality of life (QOL) [4]. OSA also increases one's risk of developing several cardiovascular-related comorbidities, including heart failure, arrhythmias, and coronary artery disease [5]. Those with apnea-hypopnea index (AHI) > 36 have a higher risk of all-cause mortality in comparison to other AHI scores (HR = 3.30; 95% CI 1.74-6.26) [6]. Patients with obstructive sleep apnea who are classified as moderate (AHI 15-30) to severe (AHI >30) have an increased risk of many adverse outcomes, specifically all-cause mortality [7]. Therefore, we hypothesize that obstructive sleep apnea has the potential to act as a predictor for cardiac events and general mortality. As a result of this, the risk of mortality in patients diagnosed with obstructive sleep apnea has become a growing and pervasive concern.

OSA is a growing public health concern, with previous studies in the literature reporting an increasing global prevalence that is upwards to 1 billion individuals [8]. Estimates within the United States suggest that approximately 15% of adults are clinically diagnosed with obstructive sleep apnea [9]. There is a large portion of the population who suffer from OSA-like symptoms, without receiving any diagnosis or treatment. This group continues to further the burden placed on the public health and medical systems. Identifying individuals diagnosed with OSA who are considered at-risk for adverse health outcomes can reduce the economic cost and burden on the healthcare system [10].

Existing evidence on the association between OSA and the risk of sudden death is insufficient and inconclusive. Our objective is to explore the association of OSA and the mortality risk. We hypothesize that in patients with OSA, there is an increased risk of all-cause mortality, cardiovascular mortality, and sudden death. To our knowledge, this is the first comprehensive systematic review and meta-analysis that explores the association between OSA and all-cause mortality, cardiovascular mortality, and sudden death.

Methods:

### **Patient and Public Involvement**

Patients or the public were not involved in the preparation or dissemination of this manuscript.

### **Search Strategy and Selection Criteria**

We comprehensively searched five databases for articles, including PubMed (MEDLINE), Cochrane, OVID (Healthstar), OVID (Medline), Scopus, and Joanna Briggs Institute EBF Database. We followed the Meta-analysis of Observational Studies in Epidemiology (MOOSE) standards for this research [11]. We identified observational studies published prior to January 1st, 2020 with reported rates of sudden death in individuals with OSA. We searched the citation list of included papers by using the snowballing method, i.e., we screened reference lists of these articles for potential eligibility as well. We did not impose any limitations related to the date of publication, language, study design, or geographical location. We predetermined defined search terms by using Medical Subject Headings (MeSH) and included combinations of “Sleep” AND “obstructive” AND “apnea” AND “sudden” AND “death” OR “sleep” AND “obstructive” AND “apnea” AND “death” OR “apnea” AND “death” AND “sleep.” We initially inputted potential studies into EndNote, which removed all duplicate

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

studies. Two reviewers (ESH and AES) independently screened titles and abstracts of the studies for inclusion eligibility. The inclusion criteria involved studies that report the rates of sudden death in both patients with and without OSA, including information on the incidence and prevalence of the outcome. Excluded studies were those that were not conducted on humans and did not report the prevalence or incidence of the outcome of interest. We excluded review papers, meta-analyses, literature reviews, commentaries, and meeting abstracts as well. We documented all excluded studies with reasons for their exclusion.

### **Quality Assessment and Data Extraction**

Since all of our studies were nonrandomized observational studies, we used the Newcastle-Ottawa Scale (NOS) for quality assessment [12]. After screening initial articles based on their titles and abstracts, ESH and AES manually screened full-text articles for continued inclusion criteria. In the event of a potential disagreement, a third researcher (PS) was recruited in order to reach a consensus. Appropriate and eligible data were extracted when screening eligible studies, including the full title, year of publication, country of publication, number of participants with and without OSA, median age of participants in both study groups, median BMI of participants with and without OSA, proportion of the sample that was male, proportion of the study sample who smoked, proportion of the study sample with hypertension and diabetes, the number of participants with OSA who died, the number of participants without OSA who died, the number of participants who did not die from both groups, the RR/OR/HR of sudden death, and other findings of interest. Studies not published in English were translated.

### **Data Analysis**

The primary outcome of interest for this meta-analysis and systematic review was the incidence of all-cause mortality in patients with OSA. There were two secondary outcomes of



1  
2  
3 interest, namely, cardiac mortality and sudden death. We used the metaprop function in R  
4  
5 Statistical Software to calculate the pooled effects of all-cause mortality, cardiac mortality, and  
6  
7 sudden death. We invoked the random-effects model with a logit transformation of proportions.  
8  
9 We applied this random-effects model, regardless of the presence of heterogeneity across studies.  
10  
11 We assessed inter-study heterogeneity using the  $I^2$  statistic, which was defined as low (25%),  
12  
13 moderate (50%), and high (75%) ( $\alpha < 0.05$ ). We conducted a meta-regression using study-level  
14  
15 descriptive statistics of age, sex, race, BMI, smoking status, diabetes, and hypertension as  
16  
17 repressors in order to improve the precision of the meta-analysis. We calculated confidence  
18  
19 intervals using the Copper-Pearson exact binomial interval method. We investigated potential  
20  
21 publication bias via funnel plots and Egger's test.  
22  
23  
24  
25

## 26 27 **Results**

28  
29  
30 As described in **Figure 1**, we identified a total of 4,613 studies from Scopus, OVID,  
31  
32 PubMed, and Joana Briggs International EBF database. We excluded 1,443 studies because they  
33  
34 were duplicates, leaving 3,170 studies to explore for inclusion. Based on the title and abstracts,  
35  
36 we excluded another 2,893 studies based on titles and abstracts, and another 249 based on full  
37  
38 text. This left us with 28 studies for the qualitative analysis and 22 studies for the quantitative  
39  
40 analysis [13-40]. Of the studies included in the quantitative analysis, 12 studies were from North  
41  
42 America, 5 from Europe, 3 from Asia, and 1 from South America.  
43  
44  
45

## 46 47 **The Association of OSA and Sudden Death**

48  
49  
50 The hazard ratio of mortality from OSA ranged from 0.80 to 9.20 (**Figure 2**). Those with  
51  
52 OSA displayed nearly twice the hazard for sudden death compared to those without OSA (HR:  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1.74 95%CI 1.4-2.10). Those in Australia had the highest rate of mortality from OSA (HR= 6.24 95%CI 1.44 -26.98), followed by South America, Europe, Asia, and North America **Figure 2**).

### **The Association of OSA and Cardiac Mortality**

The rate of cardiovascular mortality ranged from 0.80 to 4.19 (**Figure 2**). Overall, those with OSA displayed nearly twice the hazard for cardiovascular mortality compared to those without OSA (OR= 1.94, 95%CI 1.39-2.70). Only two studies reported the HR of sudden death. The HR for sudden death ranged from 1.06 to 3.28.

### **Dose-response Effect of OSA of Sudden death**

Five studies reported the HR of all-cause mortality depending on the severity of OSA. There is a dose response relationship between the relationship of OSA and sudden death. The hazard ratio for mild was 1.16 95% CI 0.70-1.93 for moderate was 1.72 95%CI 1.11-2.67, and severe was 2.87 95% CI 1.70-4.85, indicating that those with moderate to severe sleep apnea are at the highest risk of sudden death. (**Figure 5a-c**)

### **Sub-group analysis based on quality scoring**

Of the 22 studies used for quantitative analysis, one had a quality score of 6, one had a quality score of 7, three had a score of 8 and seventeen had a score of nine (**Figure 6**). We performed sub-group analysis on studies with a score of nine compared to those with less than nine. In the studies with a score of 9, the relationship between OSA and mortality was significant (HR 1.91, 95%CI 1.50-2.44) but not in the studies with a lower quality score (HR 1.52, 95%CI 0.97-2.37). However the studies with higher scores were not statistically different from those with lower scores (p=0.37).

## Discussion

To our knowledge, this is the first systematic review and meta-analysis to investigate all-cause mortality in patients with OSA. We screened six well-established databases (Pubmed-MEDLINE, OVID- HEALTH STAR, OVID-MEDLINE, Cochrane Library, Scopus, and Joana-Briggs Institute EBF Database) to identify all studies reporting the number of deaths in patients with obstructive sleep apnea. We screened 4,613 articles for inclusion criteria. After careful review, we included 28 studies. With this extensive search strategy, we discovered that (1) those with OSA displayed a hazard of sudden death that is 1.74 times higher than those without OSA, and (2) those with OSA displayed a hazard of cardiovascular-related mortality that is 1.94 times than those without OSA.

There is a large amount of evidence in research that supports the notion that OSA is associated with numerous cardiovascular conditions, including hypertension, coronary artery disease (CAD), congestive heart failure (CHF), arrhythmias, and more [41]. This association may be explained by the influence that the nervous system has on the sleep cycle in humans. OSA results in intermittent hypoxia and oxygen desaturation during sleep, which may cause over-arousal of the central nervous system (CNS) in order to increase airflow. The complex relationship between the sympathetic nervous system (SNS) and autonomic nervous system (ANS) causes a brief increase in both systolic and diastolic blood pressure (BP) during apneas [42-43]. The repeated exposure to an elevated BP continuously stresses the body. If this exposure is combined with a chronic cardiac condition, the wear on the body's regulatory systems is even greater. Therefore, we hypothesize that constant stress on the body as a result of OSA may work to explain why the mortality rates are increased in this group.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

In addition to this, patients with OSA also experience an increased level of stress on the biochemical systems in the body. Prior studies have explored the association between C-reactive protein (CRP) and obstructive sleep apnea [44]. C-reactive protein is known as an inflammatory marker. Research has found that patients with OSA have an increase in this protein, which simultaneously increases the oxidative stress they experience [44]. This chronic inflammation, which is widely prevalent in patients with OSA, is associated with endothelial cell injury. This is another hypothesis that may work to introduce some biological reasons for why mortality is increased in populations with OSA.

The methodology we employed allowed us to assess a large number of studies for inclusion. As a result of this, studies included in this meta-analysis were representative of many continents, including North America, Australia, Europe, Asia, and South America. With this being said, we were unable to identify any studies from Africa. There is a need for further research in these regions in order to identify if this association between OSA and mortality remains true. In addition to this, we only explored the association between cardiovascular mortality and sudden death in relation to OSA. Although the studies included in this review were comprehensive and thorough, they did not cover many other conditions. Factors such as obesity, diabetes, and others may be of interest to consider. Therefore, these conditions may not have been represented in this meta-analysis. Additional research should be conducted in order to explore if any other conditions can significantly increase the risk of death in patients with OSA.

## **Conclusion**

Individuals with OSA are at an increased risk for both cardiovascular mortality and sudden death. Treatments and interventions related to decreasing this risk and other adverse outcomes are necessary in order to optimize survival and quality of life (QOL).

1  
2  
3 **Author Affiliations**

4  
5 <sup>1</sup>Department of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania,  
6  
7  
8 United States of America

9  
10 <sup>2</sup>Department of Surgery, Penn State College of Medicine and Milton S. Hershey Medical Center,  
11  
12 Hershey, Pennsylvania, United States of America

13  
14 <sup>3</sup>Center for Neural Engineering, Department of Engineering, Science and Mechanics, The  
15  
16  
17 Pennsylvania State University, Pennsylvania, United States of America

18  
19  
20  
21 **Contributorship** AS, PS, ES, and VC conceived the study. AS, EH, and PS conducted the  
22  
23 literature search. AS and PS completed data analysis. AS, EH, PS, and VC interpreted the data.  
24  
25 AS, ES, and PS wrote the manuscript. All Authors agreed to the manuscript in its final form

26  
27  
28 **Patient and Public Involvement** Patients or the public were not involved in the preparation or  
29  
30 dissemination of this manuscript

31  
32  
33 **Funding** This study was not funded

34  
35  
36 **Ethics Statement** This is a systematic review and meta-analysis and individual patient was not  
37  
38 used. Therefore we did not need IRB or an ethics board approval.

39  
40 **Data Sharing Statement** All data relevant to the study are included in the article or uploaded as  
41  
42 supplementary information

43  
44  
45  
46  
47  
48  
49 **References**

50  
51  
52 [1] Arnold J, Sunilkumar M, Krishna V, Yoganand SP, Kumar MS, Shanmugapriyan D.  
53  
54 Obstructive sleep apnea. *J Pharm Bioallied Sci* 2017 Nov; 9(Supp 1): S26-S28.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731026/> (accessed Apr 20 2020).

[2] Osman AM, Carter SG, Carberry JC, Eckert DJ. Obstructive sleep apnea: current perspectives. *Nat Sci Sleep* 2018 Jan 23; 10: 21-34.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789079/> (accessed Apr 20 2020).

[3] Bonsignore MR, Baiamonte P, Mazzuca E, Castrogiovanni A, Marrone O. Obstructive sleep apnea and comorbidities: A dangerous liaison. *Multidisciplinary Respiratory Medicine* 2019 Feb 9; 14(8). <https://mrmjournal.biomedcentral.com/articles/10.1186/s40248-019-0172-9> (accessed April 24 2020).

[4] Motamedi KK, McClary AC, Amedee RG. Obstructive sleep apnea: A growing problem. *The Ochsner Journal* 2009 Fall; 9(3): 149-153.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096276/> (accessed April 24 2020)

[5] Jean-Louis G, Zizi F, Luther CT, Clinton BD, McFarlane S. Obstructive sleep apnea and cardiovascular disease: Role of the metabolic syndrome and its components. *Journal of Clinical Sleep Medicine* 2008 Jun 15; 4(3): 261-272.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2546461/> (accessed April 25 2020)

[6] Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. *NEJM* 2005 Nov 10; 353: 2034-2041.

[https://www.nejm.org/doi/10.1056/NEJMoa043104?url\\_ver=Z39.88-](https://www.nejm.org/doi/10.1056/NEJMoa043104?url_ver=Z39.88-)

[2003&rfr\\_id=ori:rid:crossref.org&rfr\\_dat=cr\\_pub%3dwww.ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov) (accessed April 25 2020)

[7] Marshall NS, Wong KKH, Cullen SRJ, Knuiman MW, Grunstein RR. Sleep apnea and 20-year follow-up for all-cause mortality, stroke, and cancer incidence and mortality in the

1  
2  
3 Busselton Health Study Cohort. *Journal of Clinical Sleep Medicine* 2014 Apr 15; 10(4).

4  
5 <https://jcsn.aasm.org/doi/10.5664/jcsn.3600> (accessed April 25 2020)

6  
7 [8] Benhafield AV, Ayas NT, Eastwood PR, Heinzer, P, Ip MSM, Morrel MJ. Estimation of the  
8 global prevalence and burden of obstructive sleep apnea: a literature-based analysis. *The Lancet*  
9  
10 2019 July 09; 7(8): 687-698. <https://www.thelancet.com/journals/lanres/article/PIIS2213->  
11  
12 [2600\(19\)30198-5/fulltext](https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(19)30198-5/fulltext) (accessed April 25 2020)

13  
14 [9] Young T, Palta M, Dempsey J, Pappard PE, Nieto FJ, Hla KM. Burden of sleep apnea:  
15  
16 Rationale, design, and major findings of the Wisconsin Sleep Cohort Study. *The Wisconsin*  
17  
18 *Medical Journal* 2009 Aug; 108(5): 246-249.

19  
20  
21 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2858234/> (accessed April 26 2020)

22  
23 [10] Tarasiuk A, Reueni H. The economic impact of obstructive sleep apnea. *Current Opinion in*  
24  
25 *Pulmonary Medicine* 2013 Nov; 19(6): 639-644.

26  
27  
28 <https://www.ncbi.nlm.nih.gov/pubmed/24060978> (accessed April 26 2020)

29  
30 [11] Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in  
31  
32 epidemiology: a proposal for reporting. *JAMA* 2000 Apr 12; 283(15): 2008-2012.

33  
34  
35 <https://www.ncbi.nlm.nih.gov/pubmed/10789670> (accessed April 26 2020)

36  
37 [12] Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing  
38  
39 the quality of nonrandomised studies in meta-analyses. *Ottawa: Ottawa Hospital Research*  
40  
41 *Institute* 2011. [http://www.ohri.ca/programs/clinical\\_epidemiology/nosgen.pdf](http://www.ohri.ca/programs/clinical_epidemiology/nosgen.pdf) (accessed April  
42  
43  
44  
45  
46  
47 26 2020)

48  
49 [13] Kerns ES, Kim ED, Meoni LA, et al. Obstructive sleep apnea increases sudden cardiac  
50  
51 death in incident hemodialysis patients. *Am J Nephrol* 2018 Aug 15; 48(2): 147-156.

52  
53  
54 <https://www.ncbi.nlm.nih.gov/pubmed/30110675> (accessed April 17 2020)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

[14] Zhang M, Li L, Fowler D, et al. Causes of sudden death in patients with obstructive sleep apnea. *J Forensic Sci* 2013 Sep; 58(5): 1171-1174.

<https://www.ncbi.nlm.nih.gov/pubmed/23865847>

(accessed April 17 2020)

[15] Gami AS, Olson EJ, Shen WK, et al. Obstructive sleep apnea and the risk of sudden cardiac death: a longitudinal study of 10,701 adults. *J Am Coll Cardiol* 2013 Aug 13; 62(7): 610-616.

<https://www.ncbi.nlm.nih.gov/pubmed/23770166> (accessed April 17 2020)

[16] Martins EF, Martinez D, da Silva FABS, et al. Disrupted day-night pattern of cardiovascular death in obstructive sleep apnea. *Sleep Med* 2017 Oct; 38: 144-150.

<https://www.ncbi.nlm.nih.gov/pubmed/28807565> (accessed April 17 2020)

[17] Szentkiralyi A, Czira ME, Molnar MZ, et al. High risk of obstructive sleep apnea is a risk factor of death censored graft loss in kidney transplant recipients: an observational cohort study.

*Sleep Med* 2011 Mar; 12(3): 267-273. <https://www.ncbi.nlm.nih.gov/pubmed/21292552>

(accessed April 17 2020)

[18] Shah NA, Yaggi HK, Concato J, Mohsenin V. Obstructive sleep apnea as a risk factor for coronary events or cardiovascular death. *Sleep Breath* 2010 Jun; 14(2): 131-136.

<https://www.ncbi.nlm.nih.gov/pubmed/19777281> (accessed April 17 2020)

[19] Sahlin C, Sandberg O, Gustafson Y, et al. Obstructive sleep apnea is a risk factor for death in patients with stroke: a 10-year follow-up. *Arch Intern Med* 2008 Feb 11; 168(3): 297-301.

<https://www.ncbi.nlm.nih.gov/pubmed/18268171> (accessed April 17 2020)

[20] Cassar A, Morgenthaler, TI, Lennon RJ, Rihal CS, Lerman A. Treatment of obstructive sleep apnea is associated with decreased cardiac death after percutaneous coronary intervention.

*JACC* 2007 Oct 02; 50(14): 1310-1314.



1  
2  
3 <https://www.sciencedirect.com/science/article/pii/S073510970702205X> (accessed April 17  
4  
5 2020)

6  
7 [21] Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep  
8  
9 apnea as a risk factor for stroke and death. *N Engl J Med* 2005 Nov 10; 353(19): 2034-2041.

10  
11 <https://www.ncbi.nlm.nih.gov/pubmed/16282178> (accessed April 17 2020)

12  
13 [22] Gami AS, Howard DE, Olson EJ, Somers VK. Day-night pattern of sudden death in  
14  
15 obstructive sleep apnea. *N Engl J Med* 2005 Mar 24; 352(12): 1206-1214.

16  
17 <https://www.ncbi.nlm.nih.gov/pubmed/15788497> (accessed April 17 2020)

18  
19 [23] Rössner S, Lagerstrand L, Persson HE, Sachs C. The sleep apnoea syndrome in obesity: risk  
20  
21 of sudden death. *J Intern Med* 1991 Aug; 230(2): 135-141.

22  
23 <https://www.ncbi.nlm.nih.gov/pubmed/1865165> (accessed April 17 2020)

24  
25 [24] Tiwari R, Lyu B, Alagusundaramoorthy S, Astor BC, Mandelbrot DA, Parajuli S.  
26  
27 Association of diagnosed obstructive sleep apnea with kidney transplant outcomes. *Clin*  
28  
29 *Transplant* 2019 Dec; 33(12). <https://www.ncbi.nlm.nih.gov/pubmed/31665552> (accessed April  
30  
31 17 2020)

32  
33 [25] Sweed RA, Hassan S, ElWahab NHA, Aref SR, Mahmoud MI. Comorbidities associated  
34  
35 with obstructive sleep apnea: a retrospective Egyptian study on 244 patients. *Sleep Breath* 2019  
36  
37 Dec; 23(4): 1079-1085. <https://www.ncbi.nlm.nih.gov/pubmed/30685854> (accessed April 17  
38  
39 2020)

40  
41 [26] Bulter MP, Emch JT, Rusechman M, et al. Apnea-hypopnea event duration predicts  
42  
43 morality in men and women in the Sleep Heart Health Study. *Am J Respir Crit Care Med* 2019  
44  
45 Apr 1; 199(7): 903-912. <https://www.ncbi.nlm.nih.gov/pubmed/30336691> (accessed April 17  
46  
47 2020)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

[27] Fan J, Wang X, Ma X, Somers VK, Nie S, Wei Y. Association of obstructive sleep apnea with cardiovascular outcomes in patients with acute coronary syndrome. *J Am Heart Assoc* 2019 Jan 22; 8(2): e010826. <https://www.ncbi.nlm.nih.gov/pubmed/30636505> (accessed April 17 2020)

[28] Shantha G, Mentias A, Pothieni NVK, et al. Role of obstructive sleep apnea on the response to cardiac synchronization therapy and all-cause mortality. *Heart Rhythm* 2018 Sep; 15(9):1283-1288. <https://www.ncbi.nlm.nih.gov/pubmed/30170662> (accessed April 17 2020)

[29] Jennum P, Baandrup L, Tønnesen P, Ibsen R, Kjellberg J. Mortality and use of psychotropic medication in sleep apnoea patients: a population-wide register-based study. *Sleep Med* 2018 Mar; 43: 19-24. <https://www.ncbi.nlm.nih.gov/pubmed/29482806> (accessed April 17 2020)

[30] Lee JE, Lee CH, Lee SJ, et al. Mortality of patients with obstructive sleep apnea in Korea. *J Clin Sleep Med* 2013 Oct 15; 9(10): 997-1002. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3778190/> (accessed April 17 2020)

[31] Yeboah J, Redline S, Johnson S, et al. Association between sleep apnea, snoring, incident cardiovascular events and all-cause mortality in an adult population: MESA. *Atherosclerosis* 2011 Dec; 219(2): 963-968. <https://www.ncbi.nlm.nih.gov/pubmed/22078131> (accessed April 17 2020)

[32] Uchôa CHG, Danzi-Soares NJ, Nunes FS, et al. Impact of OSA on cardiovascular events after coronary artery bypass surgery. *Chest* 2015 May; 147(5): 1352-1360. <https://www.ncbi.nlm.nih.gov/pubmed/25612013> (accessed April 17 2020)

[33] Anandam A, Patil M, Akinnusi M, Jaoude P, El-Solh AA. Cardiovascular mortality in obstructive sleep apnoea treated with continuous positive airway pressure or oral appliance: An

1  
2  
3 observational study. *Respirology* 2013 Nov; *18*(8): 1184-1190.

4  
5 <https://www.ncbi.nlm.nih.gov/pubmed/23731062> (accessed April 17 2020)

6  
7 [34] Marshall NS, Wong KK, Liu PY, Cullen SR, Knudman MW, Grunstein RR. Sleep apnea as  
8 an independent risk factor for all-cause mortality: The Busselton Health Study. *Sleep* Aug; *31*(8):  
9 1079-1085. <https://www.ncbi.nlm.nih.gov/pubmed/18714779> (accessed April 17 2020)

10  
11 [35] Choi JW, Song JS, Lee YJ, Won TB, Jeong DU. Increased mortality in relation to insomnia  
12 and obstructive sleep apnea in Korean patients studied with nocturnal polysomnography. *J Clin*  
13 *Sleep Med* 2017 Jan 15; *13*(1): 49-56. <https://www.ncbi.nlm.nih.gov/pubmed/27655449>  
14 (accessed April 17 2020)

15  
16 [36] Korostovtseva LS, Sviryaev YV, Zvartau NE, Konradi AO, Kalinkin AL. Prognosis and  
17 cardiovascular morbidity and mortality in prospective study of hypertensive patients with  
18 obstructive sleep apnea syndrome in St Petersburg, Russia. *Med Sci Monit* 2011 Feb 25; *17*(3):  
19 CR146-153. <https://www.ncbi.nlm.nih.gov/pubmed/21358601>(accessed April 17 2020)

20  
21 [37] Wang H, Parker JD, Newton Ge, et al. Influence of obstructive sleep apnea on mortality in  
22 patients With heart failure. *J Am Coll Cardiol* 2007 Apr 17; *49*(15): 1625-1631.  
23 <https://www.ncbi.nlm.nih.gov/pubmed/17433953> (accessed April 17 2020)

24  
25 [38] Young T, Finn L, Peppard PE, et al. Sleep disordered breathing and mortality: Eighteen-  
26 year follow-up of the Wisconsin sleep cohort. *Sleep* 2008 Aug 1; *31*(8): 1071-1078.  
27 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2542952/> (accessed April 17 2020)

28  
29 [39] Martínez-García MA, Campos-Rodríguez F, Catalán-Serra P, et al. Cardiovascular mortality  
30 in obstructive sleep apnea in the elderly: Role of long-term continuous positive airway pressure  
31 treatment: A prospective observational study. *Am J Respir Crit Care Med* 2012 Nov 01; *186*(9):  
32 909-916. <https://www.ncbi.nlm.nih.gov/pubmed/22983957> (accessed April 17 2020)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

[40] Murajo-Murro A, Eskola K, Kolari T, et al. Mortality in middle-aged men with obstructive sleep apnea in Finland. *Sleep Breath* 2013 Sep; *17*(3): 1047-1053.

<https://www.ncbi.nlm.nih.gov/pubmed/23361136> (accessed April 17 2020)

[41] Lee W, Nagubadi S, Kryger MH, Mokhlesi B. Epidemiology of Obstructive sleep apnea: a Population-based perspective. *Expert Rev Respir Med* 2008 Jun 01; *2*(3): 348-364.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727690/> (accessed April 27 2020)

[42] Bisogni V, Pengo MF, Mailino G, Rossi GP. The sympathetic nervous system and catecholamines metabolism in obstructive sleep apnoea. *J Thorac Dis* 2016 Feb; *8*(2): 243-254.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4739957/> (accessed April 27 2020)

[43] Brodovskaya TO, Grishina IF, Peretolchina TF, et al. Clues to the pathophysiology of sudden cardiac death in obstructive sleep apnea. *Cardiology* 2018 Oct; *140*(4): 247-253.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262679/> (accessed April 28 2020)

[44] Volna J, Kemlink D, Kalousova M, Vavrova J, Majerova V, et al. (2011). Biochemical oxidative stress-related markers in patients with obstructive sleep apnea. *Med Sci Monit* 2011

Sep 01; *17*(9): CR491-CR497. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3560517/>

(accessed April 28 2020)

Table 1: Studies of inclusion

AUTHOR	YEAR	COUNTRY	CONTINENT	SAMPLE SIZE (N)	STUDY TYPE	AVERAGE FOLLOW-UP	MEAN AGE	MALE (%)	COVARATES CONTROLLED	STATISTICAL MODEL FOR THE ANALYSIS	SCORE
1 2 3 4 KERNS ET AL	2018	United States	North America	558	Cohort	2 years	56	56	Age, gender, ethnicity, obstructive sleep apnea, Charlson comorbidity index, BMI. History of atrial fibrillation, left ventricular mass index, Kt/V, IDW chance, IDW change/body weight, weight-to-hip ratio	HR & OR	9
5 6 7 GAMI ET AL	2013	United States	North America	10,701	Cohort	5.3 years	53 ± 14	68	Age, hypertension, coronary artery disease, cardiomyopathy or heart failure, ventricular ectopy or NSVT, apnea-hypopnea index (per 10), mean nocturnal O <sub>2</sub> saturation (per 10%), lowest nocturnal O <sub>2</sub> saturation (per 10%)	HR	7
8 9 10 11 SZENTKIRALYI ET AL	2011	Hungary	Europe	823	Cohort	66 months	49 ± 13	59	Age sex, number of comorbidities, hypertension (presence of antihypertensive medication), duration of renal failure, eGFR, BMI, serum albumin, hemoglobin, cold ischaemic time, delayed graft function, acute rejection, HLA mismatch	HR	9
12 13 14 15 16 17 SHAH ET AL	2009	United States	North America	1,436	Cohort	2.9 years	58.5	48.7	Age, race, gender, diabetes, hypertension, atrial fibrillation, hyperlipidemia, body mass index (per 1 unit), tobacco use, alcohol use, obstructive sleep apnea (AHI ≥5)	HR	8
18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000											

Page 21 of 26	2008	Busselton	Australia	380	Cohort	13.4 years	BMJ Open	Respiratory Research	Gender, age, mean arterial pressure, high density lipoprotein cholesterol, total cholesterol, diabetes, angina, smoking categories, body mass categories, sleep apnea	HR	9	
1	2017	South Korea	Asia	4,225	Cohort	18 years		48.6	70.8	Age, gender, BMI, hypertension, diabetes	HR	9
2	2011	Russia	Europe	234	Cohort	46.4 ± 14.3 months		52.1 ± 10.4	61.2	AHI 5-14.9 per hour, AHR 12-29.9 per house, AHI ≥30 per hour, sex, age, BMI, coronary heart disease, duration of hypertension, glucose metabolism impairment, family history, alcohol use, smoking, physical activity	OR	9
3												
4												
5												
6	2007	Canada	North America	218	Cohort	2.9 ± 2.2 years		-	-	Untreated OSA, LVEF, NYHA functional class, age	HR	9
7												
8	2008	United States	North American	1,522	Cohort	18 years		48	55	Age, sex, hypertension (BP ≥ 140 systolic or ≥ 90 diastolic or use of antihypertensive medication), self-reported diagnosis of diabetes, coronary artery disease, cardiovascular disease, heart failure, myocardial infarction, cardiac surgery, stroke	HR	9
9												
10												
11												
12	2012	Spain	Europe	939	Cohort	69 months		-	-	OSA group, age, sex, type of sleep study, sleep clinic, BMI, diabetes mellitus, smoking habit, ESS, dyslipidemia, CVEs, AHT	HR	9
13												
14	2013	Finland	Europe	405	Cohort	15 years and 7 months		-	-	Age, BMI, smoking	HR	9
15												
16	2015	Brazil	South America	67	Cohort	4.5 years		57.4 ± 7.5)	74.6	Age, male sex, waist circumference, statins, ACEI/ARB, LV ejection fraction, OSA	OR	9
17												
18												

19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

Figure 1: Flow Diagram




Figure 1: Flow Diagram displaying the studies of inclusion. Of 4,613 studies explored, 28 were deemed eligible for inclusion in the qualitative analysis, and 22 studies reporting on 42,032 individuals were included in the quantitative meta-analyses.

2. All Cause Mortality




Figure 2: All cause mortality. Individuals with sleep apnea were 1.7 times as likely to die from all-cause mortality compared to those without sleep apnea (HR=1.74, 95%CI 1.44-2.10).



Figure 3. Sub-group analysis by continent




Figure 3: All cause mortality by continent. Although not statistically significant, individuals in Europe with sleep apnea had a higher incidence of mortality compared to those in North America. Australia and South America had the highest incidence of all-cause mortality from sleep apnea, although these continents urgently need more studies.

Figure 4. Cardiovascular Mortality






Figure 4: Cardiovascular Mortality. Individuals with sleep apnea were twice as likely to die from a cardiovascular related cause compared to those without sleep apnea (HR: 1.94, 95%CI 1.39-2.70).

Figure 5. Dose Response Effects of Sleep Apnea on All-Cause Mortality

A. Mild Sleep Apnea



B. Moderate Sleep Apnea



C. Severe Sleep Apnea




Figure 5: Dose response effects of sleep apnea on all-cause mortality. A. Mild sleep apnea was not associated with a significantly increased risk of mortality. B. Moderate sleep apnea increased the risk of mortality by 1.7 times (HR= 1.72, 95%CI 1.11-2.67). C. Severe Sleep apnea increased the risk of mortality by 2.9 times (HR=2.87, 95%CI 1.70-4.85).

Figure 6. Subgroup analysis high and moderate score




Figure 6: Subgroup analysis based on quality score of each paper. Although not statistically significant, publications with a higher quality scores, elicited a higher risk of mortality compared to those with a lower score.